Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6466 to 6480 of 8930 results

  1. Atrial fibrillation: management (CG180)

    This guidance has been updated and replaced by NICE guideline NG196.

    Withdrawn guideline

  2. Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)

    This guideline has been updated and replaced by NICE guideline NG238.

    Withdrawn guideline

  3. Chronic kidney disease in adults: assessment and management (CG182)

    This guidance has been updated and replaced by NICE guideline NG203.

    Withdrawn guideline

  4. Multiple sclerosis in adults: management (CG186)

    This guidance has been updated and replaced by NICE guideline NG220.

    Withdrawn guideline

  5. Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife (IPG85)

    Interventional procedures, IPG85 - Issued: August 2004 --> This guidance has been updated and replaced by NICE HealthTech guidance 608. 

    Withdrawn guidance

  6. Intramedullary distraction for lower limb lengthening (IPG197)

    This guidance has been updated and replaced by NICE HealthTech guidance 613.

    Withdrawn guidance

  7. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  8. Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)

    In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008

    Withdrawn guidance

  9. Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA12)

    This guidance has been replaced by NICE technology appraisal guidance 47. 

    Withdrawn guidance

  10. Cardiac resynchronisation therapy for the treatment of heart failure (TA120)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

    Withdrawn guidance

  11. Alteplase for the treatment of acute ischaemic stroke (TA122)

    This guidance has been updated and replaced by NICE technology appraisal guidance 264 issued in September 2012.

    Withdrawn guidance

  12. Infliximab for subacute manifestations of ulcerative colitis (TA140)

    This guidance has been updated and replaced by NICE technology appraisal guidance 329.

    Withdrawn guidance

  13. Abatacept for the treatment of rheumatoid arthritis (TA141)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 195.

    Withdrawn guidance

  14. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)

    This guidance has been replaced by NICE technology appraisal guidance 323.

    Withdrawn guidance

  15. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Withdrawn guidance